MSS Colorectal Cancer — Why Immunotherapy Does Not Work

Because an MSS tumour is largely invisible to immune cells. Checkpoint inhibitor immunotherapy releases the brakes on immune cells that have already recognised a cancer. A microsatellite stable tumour carries very few abnormal proteins. There is little for immune cells to recognise. Releasing a brake achieves almost nothing when nothing is being chased.

MSS, also reported as pMMR, is the majority. About 95 in every 100 advanced colorectal cancers fall into this group and are not candidates for checkpoint inhibitor immunotherapy on its own. Only roughly 4 to 5 in 100 metastatic colorectal cancers are MSI-High or dMMR, which is the one group where this treatment is evidence-based. Across all stages taken together the MSI-High share is higher, about 15 in 100. These ranges follow NCCN and ESMO patient guidance current as of August 2026.

This page gives the negative answer plainly, because the honest version is more useful than a hopeful one. Families often spend months, and considerable money, pursuing immunotherapy for a tumour that was never going to respond. Reading that one line early protects both hope and finances, and frees the conversation to move on to treatment that does apply.

Eligibility is confirmed by an oncology team reading your own tissue report, not by this page. If you have not been told your MMR or MSI result, that is the first thing to ask for.

Two laboratory methods describe the same biology in different words. Immunohistochemistry stains for the four mismatch repair proteins and reports dMMR or pMMR. PCR or next-generation sequencing measures instability directly and reports MSI-High, MSI-Low or MSS. MSI-Low is grouped with MSS for treatment decisions. If your report carries no MMR or MSI line at all, ask for it: NCCN guidance recommends the test for every patient diagnosed with colorectal cancer.

For the small MSI-High group, NCCN and ESMO summaries describe objective response rates broadly in the 40 to 45 percent range in advanced disease, current as of August 2026. That is a tumour-shrinkage figure seen in a proportion of patients. It is not a survival figure, and it does not carry over to MSS disease. Quoting it against an MSS tumour is where most of the false hope online begins.

• Immunotherapy with chemotherapy — the idea under test is that cell death caused by chemotherapy releases tumour proteins, giving immune cells something to recognise. Results in MSS colorectal cancer have been mixed so far.
• Immunotherapy with radiotherapy to one site — radiotherapy aimed at a single deposit is being studied as a way to make a cold tumour visible. This is the same reasoning behind interest in the abscopal effect, which remains uncommon and unpredictable.
• Immunotherapy with anti-angiogenic targeted therapy — changing the abnormal blood supply around a tumour may change the environment immune cells work in. No such combination is approved for MSS disease.
• Dual checkpoint blockade — blocking two immune checkpoints together rather than one. Side effects are more frequent with two agents, which is a real part of the trade-off being studied.
• Specific MSS subgroups — a few tumours reported as MSS still carry an unusually high number of DNA errors, for example through a POLE or POLD1 change. Identifying them needs sequencing rather than assumption.

This is written so you can raise trials with your own oncologist. It is not an offer of enrolment, and no benefit is claimed here for any investigational combination. Whether a trial is open to you is decided by that trial's own eligibility criteria and its investigators.

Trials recruiting in India are listed on the Clinical Trials Registry – India (CTRI), maintained by ICMR. Ask your treating team to check whether anything listed there is relevant to your disease, your prior treatment and your fitness.

• Chemotherapy is still the backbone — combination chemotherapy remains the most established treatment for advanced MSS colorectal cancer. The regimen is chosen on your fitness, prior treatment and pattern of disease, and reviewed as you go.
• RAS, BRAF and HER2 change the plan — these molecular results guide targeted treatment choices in MSS disease. A molecular report is never wasted because the MSI line reads stable, so ask whether the full panel was done.
• Surgery and local treatment where spread is limited — when disease is confined to a small number of sites, surgery or local ablative treatment is weighed alongside systemic treatment at tumour board, not ruled out by stage alone.
• A clinical trial, raised early — for MSS disease, trials are where combination immunotherapy is being studied. Asking while you are fit and have had fewer prior lines usually keeps more options open than asking at the end.
• Supportive care runs alongside, not instead — nutrition, pain control and psycho-oncology support are part of the plan from the beginning, not a step that starts when options narrow.

• Was MMR or MSI testing actually done on my tissue, and which method was used?
• Were RAS, BRAF and HER2 reported, and does any of them change my treatment?
• What is the plan for the next three months, and what will tell us it is working?
• Is any trial open that I could be considered for now rather than later?
• What will this cost, and what does ArogyaSri, CGHS or my insurance cover?

• Liver cancer is the GI site where immunotherapy is used most, and eligibility there turns on liver function rather than on MSI. Immunotherapy for Liver Cancer (Hepatocellular Carcinoma) explains how that assessment works.
• If hepatitis B or cirrhosis is part of your history, the screening described in step 4 above matters even more. Immunotherapy With Hepatitis B or Cirrhosis sets out the monitoring and antiviral protocol in full.
• Pancreatic and biliary cancers face the same cold-tumour problem described on this page, and the honest answer there is similar. Immunotherapy for Pancreatic and Biliary Cancers covers where the narrow exceptions sit.
• For how immunotherapy is delivered, monitored and paid for at CION, including day-care scheduling and scheme cover, see Immunotherapy at CION Cancer Clinics.

Not sure which group your report puts you in? Book a free consultation and a medical oncologist will read it with you.